Solid Biosciences Initiates FALCON Clinical Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 12 2026
0mins
Should l Buy SLDB?
Solid Biosciences announced that the first participant has been dosed in FALCON, the Company's Phase 1b, first-in-human clinical trial evaluating SGT-212. Bo Cumbo, President & CEO of Solid Biosciences, commented: "Initiating dosing in the FALCON trial represents the culmination of years of dedicated work towards moving the needle for the FA community. By aiming to precisely target the key structures responsible for neurologic morbidity and cardiac manifestations, we intend to address both quality-of-life and mortality drivers in this devastating disease, a key differentiation of SGT-212 when compared to potential alternatives. The dual-route administration strategy employed by SGT-212 exemplifies Solid's mission to be bold in our vision, audacious in our science and steadfast in our commitment to bringing potentially life-changing medicines to patients."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SLDB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SLDB
Wall Street analysts forecast SLDB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SLDB is 14.88 USD with a low forecast of 9.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
10 Buy
0 Hold
0 Sell
Strong Buy
Current: 6.230
Low
9.00
Averages
14.88
High
20.00
Current: 6.230
Low
9.00
Averages
14.88
High
20.00
About SLDB
Solid Biosciences Inc. is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The Company is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy and additional assets for the treatment of genetic cardiac and neuromuscular disease. It also has two cardiac pipeline gene transfer programs, SGT-401 for BAG3-mediated DCM, which is in early preclinical development, and SGT-701 for RBM20 DCM, which is in the discovery stage. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Solid Biosciences CEO to Present at Biotech Summit 2026
- Executive Presentation: Solid Biosciences CEO Bo Cumbo will present at the Guggenheim Emerging Outlook: Biotech Summit on February 12, 2026, at 10:30 AM ET, showcasing the company's advancements in precision genetic medicine, which is expected to attract attention from investors and industry experts.
- Webcast Availability: The presentation will be available via live webcast on the company's investor events page, with a replay archived for 30 days, ensuring that investors who cannot attend live can access key information, thereby enhancing the company's transparency.
- Mission and Vision: Solid Biosciences focuses on developing gene therapy candidates for rare neuromuscular and cardiac diseases, aiming to improve the daily lives of patients, particularly those affected by Duchenne muscular dystrophy, reflecting the company's deep commitment to patient care.
- Diverse Pipeline: The company is advancing various gene therapy candidates, including SGT-003 for Duchenne muscular dystrophy and SGT-212 for Friedreich's ataxia, demonstrating its innovative potential and competitive edge in the biopharmaceutical sector.
See More
Sarepta Shares Rise as 3-Year Elevidys Study Results Offer Promise.
- Positive Study Results: Sarepta Therapeutics announced positive top-line results for its study on Elevidys, a treatment for Duchenne muscular dystrophy.
- Stock Market Reaction: Following the announcement, Sarepta's stock experienced a significant increase.
See More
Solid Biosciences (SLDB) Completes Enrollment for SGT-003 Clinical Trial
- Trial Enrollment Completed: Solid Biosciences announced full enrollment in its Phase 1/2 study for SGT-003 targeting Duchenne muscular dystrophy, with an expected 50-60 patients, indicating significant progress in the gene therapy sector.
- Patient Safety Update: As of January 9, 2025, 33 patients have received SGT-003, showing general tolerability, which enhances confidence in its safety profile, following a previous update on 23 patients' positive responses.
- FDA Interaction Progress: The company expects to provide updates on the Phase 3 confirmatory trial design for SGT-003 by mid-2026, which will offer crucial guidance for future clinical development and may expedite the drug's market entry.
- Positive Market Reaction: Following the enrollment announcement, Solid Biosciences' stock rose on Wednesday, reflecting investor optimism regarding the company's prospects in treating muscle-wasting disorders, potentially driving future funding and partnership opportunities.
See More
Solid Biosciences (SLDB) Receives FDA Orphan Drug Designation for SGT-212, Phase 1b Trial Initiated
- Orphan Drug Designation: Solid Biosciences' SGT-212 has received Orphan Drug designation from the FDA, marking a significant advancement in the treatment of Friedreich's Ataxia (FA) and potentially enhancing its market competitiveness.
- Trial Initiation: The company has completed the first participant dosage in the FALCON trial, with initial data expected in the second half of 2026, which will provide critical safety and tolerability insights for FA treatment.
- Dual Administration Method: SGT-212 employs a dual-route administration, including an IDN infusion directly into the cerebellar dentate nuclei and an intravenous infusion, aimed at addressing the neurological, cardiac, and systemic manifestations of FA to improve therapeutic outcomes.
- Market Potential: With approximately 5,000 patients in the U.S. and 15,000 in Europe suffering from FA, the development of SGT-212 not only fills a significant market gap but also offers new treatment hope for patients, enhancing the company's long-term growth prospects.
See More
Solid Biosciences Receives FDA Fast Track and Orphan Drug Designations for SGT-212, Initiates Phase 1b Trial
- FDA Designations: Solid Biosciences' SGT-212 has received Orphan Drug, Fast Track, and Rare Pediatric Disease designations from the FDA, indicating its potential value in treating Friedreich's ataxia and likely accelerating its development timeline.
- Trial Initiation: The first participant has been dosed in the FALCON trial for SGT-212, with initial data expected in H2 2026, which could provide new treatment hope for FA patients.
- Innovative Delivery Method: SGT-212 employs a dual-route administration via precise MRI-guided intradentate nucleus infusion followed by IV infusion, aiming to restore therapeutic frataxin levels to improve neurological, cardiac, and systemic symptoms of FA.
- Market Potential: With approximately 5,000 patients affected by Friedreich's ataxia in the U.S., the development of SGT-212 not only addresses a significant market gap but also presents substantial commercial opportunities and market exclusivity for Solid Biosciences.
See More
Solid Biosciences Grants 7,000 RSUs to New Employee as Inducement
- Employee Incentive Program: Solid Biosciences grants 7,000 restricted stock units (RSUs) to a newly hired employee, vesting in four equal installments over four years, aimed at attracting and retaining key talent, thereby enhancing the company's competitive edge.
- Compliance Assurance: This stock grant complies with Nasdaq Listing Rule 5635(c)(4) as an inducement for the employee's acceptance of employment, ensuring the company's adherence to regulations and transparency in attracting high-quality talent.
- Strategic Development Focus: Solid Biosciences is dedicated to developing precision gene therapies for rare neuromuscular and cardiac diseases, and the RSU grant will help attract more professionals in this field, advancing its research pipeline.
- Mission Reinforcement: Through this incentive, Solid Biosciences further strengthens its mission to improve the daily lives of patients with rare diseases, ensuring ongoing innovation and development in the gene therapy sector.
See More
Solid Biosciences CEO to Present at Biotech Summit 2026
- Executive Presentation: Solid Biosciences CEO Bo Cumbo will present at the Guggenheim Emerging Outlook: Biotech Summit on February 12, 2026, at 10:30 AM ET, showcasing the company's advancements in precision genetic medicine, which is expected to attract attention from investors and industry experts.
- Webcast Availability: The presentation will be available via live webcast on the company's investor events page, with a replay archived for 30 days, ensuring that investors who cannot attend live can access key information, thereby enhancing the company's transparency.
- Mission and Vision: Solid Biosciences focuses on developing gene therapy candidates for rare neuromuscular and cardiac diseases, aiming to improve the daily lives of patients, particularly those affected by Duchenne muscular dystrophy, reflecting the company's deep commitment to patient care.
- Diverse Pipeline: The company is advancing various gene therapy candidates, including SGT-003 for Duchenne muscular dystrophy and SGT-212 for Friedreich's ataxia, demonstrating its innovative potential and competitive edge in the biopharmaceutical sector.
See More
Sarepta Shares Rise as 3-Year Elevidys Study Results Offer Promise.
- Positive Study Results: Sarepta Therapeutics announced positive top-line results for its study on Elevidys, a treatment for Duchenne muscular dystrophy.
- Stock Market Reaction: Following the announcement, Sarepta's stock experienced a significant increase.
See More
Solid Biosciences (SLDB) Completes Enrollment for SGT-003 Clinical Trial
- Trial Enrollment Completed: Solid Biosciences announced full enrollment in its Phase 1/2 study for SGT-003 targeting Duchenne muscular dystrophy, with an expected 50-60 patients, indicating significant progress in the gene therapy sector.
- Patient Safety Update: As of January 9, 2025, 33 patients have received SGT-003, showing general tolerability, which enhances confidence in its safety profile, following a previous update on 23 patients' positive responses.
- FDA Interaction Progress: The company expects to provide updates on the Phase 3 confirmatory trial design for SGT-003 by mid-2026, which will offer crucial guidance for future clinical development and may expedite the drug's market entry.
- Positive Market Reaction: Following the enrollment announcement, Solid Biosciences' stock rose on Wednesday, reflecting investor optimism regarding the company's prospects in treating muscle-wasting disorders, potentially driving future funding and partnership opportunities.
See More
Solid Biosciences (SLDB) Receives FDA Orphan Drug Designation for SGT-212, Phase 1b Trial Initiated
- Orphan Drug Designation: Solid Biosciences' SGT-212 has received Orphan Drug designation from the FDA, marking a significant advancement in the treatment of Friedreich's Ataxia (FA) and potentially enhancing its market competitiveness.
- Trial Initiation: The company has completed the first participant dosage in the FALCON trial, with initial data expected in the second half of 2026, which will provide critical safety and tolerability insights for FA treatment.
- Dual Administration Method: SGT-212 employs a dual-route administration, including an IDN infusion directly into the cerebellar dentate nuclei and an intravenous infusion, aimed at addressing the neurological, cardiac, and systemic manifestations of FA to improve therapeutic outcomes.
- Market Potential: With approximately 5,000 patients in the U.S. and 15,000 in Europe suffering from FA, the development of SGT-212 not only fills a significant market gap but also offers new treatment hope for patients, enhancing the company's long-term growth prospects.
See More
Solid Biosciences Receives FDA Fast Track and Orphan Drug Designations for SGT-212, Initiates Phase 1b Trial
- FDA Designations: Solid Biosciences' SGT-212 has received Orphan Drug, Fast Track, and Rare Pediatric Disease designations from the FDA, indicating its potential value in treating Friedreich's ataxia and likely accelerating its development timeline.
- Trial Initiation: The first participant has been dosed in the FALCON trial for SGT-212, with initial data expected in H2 2026, which could provide new treatment hope for FA patients.
- Innovative Delivery Method: SGT-212 employs a dual-route administration via precise MRI-guided intradentate nucleus infusion followed by IV infusion, aiming to restore therapeutic frataxin levels to improve neurological, cardiac, and systemic symptoms of FA.
- Market Potential: With approximately 5,000 patients affected by Friedreich's ataxia in the U.S., the development of SGT-212 not only addresses a significant market gap but also presents substantial commercial opportunities and market exclusivity for Solid Biosciences.
See More
Solid Biosciences Grants 7,000 RSUs to New Employee as Inducement
- Employee Incentive Program: Solid Biosciences grants 7,000 restricted stock units (RSUs) to a newly hired employee, vesting in four equal installments over four years, aimed at attracting and retaining key talent, thereby enhancing the company's competitive edge.
- Compliance Assurance: This stock grant complies with Nasdaq Listing Rule 5635(c)(4) as an inducement for the employee's acceptance of employment, ensuring the company's adherence to regulations and transparency in attracting high-quality talent.
- Strategic Development Focus: Solid Biosciences is dedicated to developing precision gene therapies for rare neuromuscular and cardiac diseases, and the RSU grant will help attract more professionals in this field, advancing its research pipeline.
- Mission Reinforcement: Through this incentive, Solid Biosciences further strengthens its mission to improve the daily lives of patients with rare diseases, ensuring ongoing innovation and development in the gene therapy sector.
See More
